Gilead Sciences | GILD - Pre Tax Profit



Gilead Sciences reported $2.43B in Pre-Tax Profit for its fiscal quarter ending in June of 2025.


Pre Tax Profit Change Date
AbbVie USD 1.66B 3.15B Mar/2025
Agios Pharmaceuticals USD -112020000 22.73M Jun/2025
ALKERMES USD 104.84M 79.35M Jun/2025
Alnylam Pharmaceuticals USD -35358000 6.24M Jun/2025
Amgen USD 1.57B 405M Jun/2025
Biogen USD 744M 432.8M Jun/2025
BioMarin Pharmaceutical USD 297.87M 59.78M Jun/2025
Bristol-Myers Squibb USD 1.77B 1.2B Jun/2025
Eli Lilly USD 6.78B 3.32B Jun/2025
Gilead Sciences USD 2.43B 780M Jun/2025
GlaxoSmithKline GBP 1.89B 221M Jun/2025
Glaxosmithkline USD 1.89B 230.76M Jun/2025
Incyte USD 558.01M 323.82M Jun/2025
J&J USD 13.63B 8.21B Mar/2025
Merck USD 6.77B 864M Jun/2025
Moderna USD -818000000 146M Jun/2025
Neurocrine Biosciences USD 159.5M 144.8M Jun/2025
Novartis USD 4.53B 124M Jun/2025
Pfizer USD 3.04B 259M Jun/2025
PTC Therapeutics USD -71052000 1B Jun/2025
Regeneron Pharmaceuticals USD 1.52B 613.7M Jun/2025
Sanofi EUR 1.42B 734M Jun/2025
Sarepta Therapeutics USD 153.64M 537.16M Jun/2025
United Therapeutics USD 408.4M 15.1M Jun/2025
Vertex Pharmaceuticals USD 1.28B 552.6M Jun/2025